EVOTEC SE ADR 1/2 O.N. (EVTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, EVOTEC SE ADR 1/2 O.N. (EVTA) has a cash flow conversion efficiency ratio of 0.078x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€63.63 Million ≈ $74.39 Million USD) by net assets (€813.70 Million ≈ $951.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See EVTA net asset quality index to measure how much of total assets are equity-financed.
EVOTEC SE ADR 1/2 O.N. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how EVOTEC SE ADR 1/2 O.N.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check EVTA operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
EVOTEC SE ADR 1/2 O.N. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of EVOTEC SE ADR 1/2 O.N. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
United States Antimony Corporation
NYSE MKT:UAMY
|
-0.054x |
|
Evergreen International Storage & Transport Corp
TW:2607
|
0.029x |
|
Capital City Bank Group
NASDAQ:CCBG
|
0.028x |
|
SK Securities Co Ltd Preference Shares
KO:001515
|
-0.069x |
|
Lonkey Industrial Co Ltd Guangzhou
SHE:000523
|
0.006x |
|
BFI Finance Indonesia Tbk
JK:BFIN
|
0.064x |
|
Sundiro Holding Co Ltd
SHE:000571
|
-0.031x |
|
Guanghui Logistics Co Ltd
SHG:600603
|
0.005x |
Annual Cash Flow Conversion Efficiency for EVOTEC SE ADR 1/2 O.N. (2021–2025)
The table below shows the annual cash flow conversion efficiency of EVOTEC SE ADR 1/2 O.N. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see EVOTEC SE ADR 1/2 O.N. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €813.70 Million ≈ $951.31 Million |
€-9.18 Million ≈ $-10.73 Million |
-0.011x | -158.97% |
| 2024-12-31 | €952.52 Million ≈ $1.11 Billion |
€18.22 Million ≈ $21.30 Million |
0.019x | -41.21% |
| 2023-12-31 | €1.12 Billion ≈ $1.31 Billion |
€36.44 Million ≈ $42.60 Million |
0.033x | -81.23% |
| 2022-12-31 | €1.19 Billion ≈ $1.39 Billion |
€205.81 Million ≈ $240.61 Million |
0.173x | +88.66% |
| 2021-12-31 | €1.38 Billion ≈ $1.61 Billion |
€126.60 Million ≈ $148.01 Million |
0.092x | -- |
About EVOTEC SE ADR 1/2 O.N.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more